Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2485-2493

  Gasparini, G ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ENDOTHELIAL CELL GROWTH FACTOR; FLUOROURACIL; METHOTREXATE;

ANGIOGENESIS; BREAST CANCER; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 0030502296     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00376-0     Document Type: Article

References (75)

1. 1. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993, 85, 1206-1219.
2. 2. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995, 333, 1757-1763.
3. 3. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991, 324, 1-8.
4. 4. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992, 340, 1120-1124.
5. 5. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in earlystage breast carcinoma. J Natl Cancer Inst 1992, 84, 1875-1887.
6. 6. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantification and prognosis in invasive breast carcinoma. Hum Pathol 1992, 23, 755-761.
7. 7. Visscher DW, Smilanetz S, Drozdowicz S, Wykes SM. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol Histol 1993, 15, 88-92.
8. 8. Van Hoef MEHN, Knox WF, Dhesi SS, Howell A, Schor AM. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993, 29A, 1141-1145.
9. 9. Khanuja PS, Gimotty P, Fregene T, George J, Pienta KJ. Angiogenesis quantitation as a prognostic factor for primary breast carcinoma 2 cms or less. In Salmon SE, ed. Adjuvant Therapy of Cancer VII. Hagerstown, Maryland, Raven Publishers, 1993, 226-232.
10. 10. Obermair A, Czerwenka K, Kurz C, Buxhaum P, Schemper M, Sevelda P. Influence of tumoral microvessel density on the recurrence-free survival in human breast cancer: preliminary results. Onkologie 1994, 17, 44-49.
11. 11. Ogawa Y, Chung Y-S, Nakata B, et al. Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer 1995, 71, 1297-1301.
12. 12. Hall NR, Fish DE, Hunt N, Goldin RD, Giillou PJ, Monson JRT. Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1992, 1, 223-229.
13. 13. Fox SB, Turner GDH, Leek RD, et al. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecular expression in tumor endothelium. Breast Cancer Res Treat 1995, 36, 219-226.
14. 14. Costello P, McCann A, Carney DN, et al. Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 1995, 26, 1196-1200.
15. 15. Goulding H, Nik Abdul Rashid NF, Robertson JF, et al. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol 1995, 26, 1196-1200.
16. 16. Siitonen SM, Haapasalo HK, Rantala IS, Helin HJ, Isola JJ. Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Modern Pathol 1995, 8, 745-752.
17. 17. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993, 55, 371-374.
18. 18. Gasparini G, Barbareschi M, Boracchi P, et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am 1995, 1, 131-141.
19. 19. Macaulay VM, Fox SB, Zhang H, et al. Breast cancer angiogenesis and tamoxifen resistance. Endocrine-Rel Cancer 1995, 2, 97-103.
20. 20. Bevilacqua P, Barbareschi M, Verderio P, et al. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma. Results of a multiparametric study. Breast Cancer Res Treat 1995, 36, 205-217.
21. 21. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995, 36, 193-204.
22. 22. Obermair A, Kurz C, Czerwenka K, et al. Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer 1995, 62, 126-131.
23. 23. Axelsson K, Ljung B-ME, More II DH, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995, 87, 997-1008.
24. 24. Gasparini G, Fox SB, Verderio P, et al. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clin Cancer Res 1996, 2, 1191-1198.
25. 25. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
26. 26. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995, 1, 27-31.
27. 27. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79, 185-188.
28. 28. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977, 195, 880-881.
29. 29. Jensen HM, Chen I, DeValut MR, Lewis AE. Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 1982, 218, 293-295.
30. 30. McLeskey SW, Kurebayashi J, Honig SF, et al. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 1993, 53, 2168-2177.
31. 31. Costa M, Danesi A, Agen C, et al. MCF-10A cells infected with the int-2 oncogene induce angiogenesis in the chick choriollantoic membrane and in the rat mesentary. Cancer Res 1994, 54, 9-11.
32. 32. Zhang H-T, Craft P, Scott PAE, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells, J Natl Cancer Inst 1995, 87, 213-219.
33. 33. Zajchowski DA, Band V, Trask DK, Kling D, Connolly JL, Sager R. Suppression of tumor-forming ability and related traits in MCF-7 human breast cancer cell by fusion with immortal mammary epithelial cells. Cell Biol 1990, 87, 2314-2318.
34. 34. Volpert OV, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 1995, 36, 119-126.
35. 35. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994, 54, 6504-6511.
36. 36. Pierce DF, Gorska AE, Chytil A, et al. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc Natl Acad Sci USA 1995, 92, 4254-4258.
37. 37. Brem SS, Jensen HM, Gullino PM. Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 1978, 41, 239-244.
38. 38. Guidi AJ, Fisher L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994, 86, 614-619.
39. 39. Guinebretiere JM, Monique GL, Gavoille A, Bahi J, Contesso G. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994, 86, 635-636.
40. 40. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA, Anti-integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96, 1815-1822.
41. v integrins. Science 1995, 270, 1500-1502.
42. 42. Friedrichs K, Ruiz P, Franke F, Gille I, Terpe H-J, Imhof BA. High expression level of α6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 1995, 55, 901-906.
43. 43. Hildenbrand R, Dilger I, Hörlin A, Stutte HJ. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995, 72, 818-823.
44. 44. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature Med 1996, 2, 209-216.
45. 45. Seymour L, Bezwoda WR. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat 1994, 32, 229-233.
46. 46. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 1995, 64, 79-82.
47. 47. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995, 1, 961-964.
48. 48. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996, 2, 821-826.
49. 49. Pennault-Llorca F, Bertucci F, Adelaide J, et al. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 1995, 61, 170-176.
50. 50. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994, 86, 356-361.
51. 51. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1995, 1, 1031-1034.
52. 52. Toi M, Hoshima S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994, 85, 1045-1049.
53. 53. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995, 346, 1334-1335.
54. 54. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996, 2, 689-692.
55. 55. Bevilacqua P, Boracchi P, Gasparini G. Prognostic indicators for early-stage breast carcinoma - Part II: Value of cathepsin D expression, detected by immunocytochemistry. A multiparametric study. Int J Oncol 1994, 5, 559-564.
56. 56. Gasparini G, Bevilacqua P, Boracchi P, et al. Prognostic value of p53 expression in early-stage breast carcinoma compared with tumour angiogenesis, epidermal growth factor receptor, c-erbB-2, cathepsin D, DNA ploidy, parameters of cell kinetics and conventional features. Int J Oncol 1994, 4, 155-162.
57. 57. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995, 13, 765-782.
58. 58. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996, 32A, 2474-2484.
59. 59. Barbareschi M, Weidner N, Gasparini G, et al. Microvessel density quantification in breast carcinoma. Assessment by light microscopy vs. a computer-aided image analysis system. Appl Immunohistochem 1995, 3, 75-84.
60. 60. Gasparini G, Weidner N, Bevilacqua P, et al Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994, 12, 454-466.
61. 61. Gasparini G, Barbareschi M, Boracchi P, et al. 67 kDa laminin-receptor expression adds prognostic information to intratumoral microvessel density in node-negative breast cancer. Int J Cancer 1995, 60, 604-610.
62. 62. Gasparini G. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma (tetter)-J Natl Cancer lnst 1995, 87, 1799-1801.
63. 63. Fox SB, Westwood M, Moghaddam A, et al. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 1996, 73, 275-280.
64. 64. Fox SB, Gatter KC, Bicknell R, et al. Relationship of endothelial proliferation to tumor vascularity in human breast cancer. Cancer Res 1993, 53, 4161-4163.
65. 65. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 1994, 144, 1188-1194.
66. 66. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996, 2, 613-618.
67. 67. Barbareschi M, Gasparini G, Morelli L, Forti S, Dalla Palma P. Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res Treat 1995, 36, 181-192.
68. 68. Gasparini G. Quantification of intratumoral vascularisation predicts metastasis in human invasive solid tumours. Oncol Rep 1994, 1, 7-12.
69. 69. Gasparini G. Angiogenesis in preneoplastic and neoplastic lesions. Cancer J 1995, 8, 91-93.
70. 70. Gasparini G. Biological and clinical role of angiogenesis in breast cancer. Breast Cancer Res Treat 1995, 36, 103-107.
71. 71. Gasparini G, Presta M. Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation. Ann Oncol 1996, 7, 441-444.
72. 72. Gasparini G. The role of angiogenesis in tumour progression of breast cancer. In Calvo F, Crépin M, Magdelenat H, eds. Breast Cancer. Advances in Biology and Therapeutics. Montrouge, John Libbey Eurotext, 1996, 167-173.
73. 73. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995, 55, 3629-3633.
74. 74. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
75. 75. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991, 51, 6180-6184.